Edition:
United States

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

11.00USD
2:18pm EST
Change (% chg)

$0.45 (+4.27%)
Prev Close
$10.55
Open
$10.50
Day's High
$11.05
Day's Low
$10.50
Volume
2,805
Avg. Vol
7,072
52-wk High
$13.75
52-wk Low
$5.15

Latest Key Developments (Source: Significant Developments)

Cellular Biomedicine Group reports qtrly ‍loss per share $0.43
Thursday, 9 Nov 2017 08:30am EST 

Nov 9 (Reuters) - Cellular Biomedicine Group Inc :Cellular Biomedicine Group reports third quarter financial results and recent operational highlights.Cellular Biomedicine Group Inc- ‍$16.3 million cash and cash equivalents as of September 30, 2017 as compared to $27.3 million as of June 30, 2017​.Cellular Biomedicine Group Inc - Qtrly ‍loss per share $0.43​.Cellular Biomedicine Group Inc - Qtrly net sales and revenue $106,787 versus $10,012‍​.  Full Article

Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processes
Monday, 6 Nov 2017 07:19am EST 

Nov 6 (Reuters) - Cellular Biomedicine Group Inc :Thermo Fisher Scientific and Cellular Biomedicine Group announce strategic partnership to develop manufacturing processes.Cellular Biomedicine Group Inc - ‍partnership focuses on research and development of an automated cell therapy manufacturing system​.  Full Article

BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin
Tuesday, 19 Sep 2017 06:30am EDT 

Sept 19 (Reuters) - Cellular Biomedicine Group Inc :BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin.  Full Article

Cellular Biomedicine Q2 ‍loss per share $0.43​
Tuesday, 8 Aug 2017 04:31pm EDT 

Aug 8 (Reuters) - Cellular Biomedicine Group Inc ::Cellular Biomedicine Group reports second quarter and first half 2017 financial results and business highlights.Cellular Biomedicine Group Inc - ‍cash and cash equivalents as of June 30, 2017 were $27.3 million compared to $39.3 million as of December 31, 2016​.Cellular Biomedicine Group Inc qtrly ‍loss per share $0.43​.  Full Article

Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trial
Monday, 15 May 2017 06:23am EDT 

May 15 (Reuters) - Cellular Biomedicine Group Inc :Cellular Biomedicine Group (CBMG) announces the addition of a second clinical site in the expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I clinical trial for its CARD-1 trial in patients with non-hodgkin lymphoma (NHL).Cellular Biomedicine Group Inc - on track to share topline clinical data in Q4 of this year as it becomes available from CARD-1 trial.  Full Article

Cellular Biomedicine Q1 net loss per share $0.43
Monday, 8 May 2017 04:01pm EDT 

May 8 (Reuters) - Cellular Biomedicine Group Inc ::Cellular Biomedicine Group reports first quarter 2017 financial results and provides business highlights.Cellular Biomedicine Group Inc - qtrly net loss per share $ 0.43.Cellular Biomedicine Group Inc - cash and cash equivalents as of march 31, 2017 were $33.4 million compared to $39.3 million as of December 31, 2016.  Full Article

Cellular Biomedicine, GE Healthcare Life Sciences China established strategic research collaboration
Monday, 10 Apr 2017 08:05am EDT 

Cellular Biomedicine Group Inc : Cellular Biomedicine - co, GE Healthcare Life Sciences China established strategic research collaboration .Cellular Biomedicine - collaboration to co-develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing.  Full Article

Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31
Tuesday, 14 Mar 2017 06:00am EDT 

Cellular Biomedicine Group Inc : Cellular biomedicine group reports full-year 2016 financial results and recent operational progress .Cellular biomedicine group inc- had working capital of $38.3 million as of december 31, 2016 compared to $13.7 million as of december 31, 2015.  Full Article

Cellular Biomedicine Group announces resale of up to 5.1 mln shares of common stock for sale by selling stockholders
Monday, 20 Jun 2016 05:25pm EDT 

Cellular Biomedicine Group Inc :Resale of up to 5.1 million shares of common stock for sale by the selling stockholders - SEC filing.  Full Article

Cellular Biomedicine reports Q1 results
Monday, 9 May 2016 04:01pm EDT 

Cellular Biomedicine Group Inc : Cellular Biomedicine Group Inc says cash and cash equivalents as of march 31, 2016 were $15.7 million compared to $14.9 million as of december 31, 2015 . Cellular biomedicine group reports first quarter 2016 financial results and provides business highlights .Q1 revenue $488,500 versus $603,400.  Full Article

BRIEF-Cellular Biomedicine Group reports qtrly ‍loss per share $0.43

* Cellular Biomedicine Group reports third quarter financial results and recent operational highlights